HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.

Abstract
The N-terminal cleavage product of human insulin-like growth factor-1 (IGF-1) in the brain is the tripeptide molecule Glypromate (Gly-Pro-Glu). Glypromate has demonstrated neuroprotective effects in numerous in vitro and in vivo models of brain injury and is in clinical trials for the prevention of cognitive impairment following cardiac surgery. NNZ-2566 is a structural analogue of Glypromate, resulting from alpha-methylation of the proline moiety, which has improved the elimination half-life and oral bioavailability over the parent peptide. In vivo, NNZ-2566 reduces injury size in rats subjected to focal stroke. An intravenous infusion of NNZ-2566 of 4 h duration (3-10 mg/kg/h), initiated 3 h after endothelin-induced middle-cerebral artery constriction, significantly reduced infarct area as assessed on day 5. Neuroprotective efficacy in the MCAO model was also observed following oral administration of the drug (30-60 mg/kg), when formulated as a microemulsion. In vitro, NNZ-2566 significantly attenuates apoptotic cell death in primary striatal cultures, suggesting attenuation of apoptosis is one mechanism of action underlying its neuroprotective effects. NNZ-2566 is currently in clinical trials for the treatment of cognitive deficits following traumatic brain injury, and these data further support the development of the drug as a neuroprotective agent for acute brain injury.
AuthorsMichael J Bickerdike, Gregory B Thomas, David C Batchelor, Ernest S Sirimanne, Wing Leong, Hai Lin, Frank Sieg, Jingyuan Wen, Margaret A Brimble, Paul W Harris, Peter D Gluckman
JournalJournal of the neurological sciences (J Neurol Sci) Vol. 278 Issue 1-2 Pg. 85-90 (Mar 15 2009) ISSN: 0022-510X [Print] Netherlands
PMID19157421 (Publication Type: Journal Article)
Chemical References
  • NNZ 2566
  • Neuroprotective Agents
  • Oligopeptides
  • Okadaic Acid
  • glycyl-prolyl-glutamic acid
Topics
  • Administration, Oral
  • Animals
  • Apoptosis (drug effects)
  • Blood Chemical Analysis
  • Brain (drug effects, pathology)
  • Disease Models, Animal
  • Female
  • Infarction, Middle Cerebral Artery (drug therapy, pathology)
  • Infusions, Intravenous
  • Male
  • Microdialysis
  • Neuroprotective Agents (administration & dosage, pharmacokinetics, therapeutic use)
  • Okadaic Acid (pharmacology)
  • Oligopeptides (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Stroke (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: